Synapse - Works

Results (22057)

A phase 3, multicenter, randomized, open-label trial of [fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) vs investigator's choice in HER2-low breast cancer (DESTINY-Breast04)

Meeting Abstract

Modi, S.; Ohtani, S.; Lee, C.; Wang, Y.; Saxena, K.; Cameron, D. A.
Cancer Research (2020)

Fulltext@MSK | Save

RAD51B loss-of-function variants confer susceptibility to hereditary breast and ovarian cancers and result in tumors with genomic features of homologous recombination repair defects

Meeting Abstract

Mandelker, D.; Mukherjee, S.; Setton, J.; Selenica, P.; Kemel, Y.; Ceyhan-Birsoy, O.; Sheehan, M.; Tkachuk, K.; Brown, D. N.; Powell, S.; more...
Cancer Research (2020)

Fulltext@MSK | Save

Phase 1/2 first-in-human study of U3-1402, an anti-human epidermal growth factor receptor 3 (HER3) antibody-drug conjugate, in HER3-expressing advanced/unresectable or metastatic breast cancer, including those with triple negative breast cancer (TNBC) or HER3-low disease

Meeting Abstract

Krop, I.; Masuda, N.; Kogawa, T.; Takahashi, S.; Yonemori, K.; Inoue, K.; Nakayama, T.; Yamamoto, Y.; Alvarez, R.; Toyama, T.; more...
Cancer Research (2020)

Fulltext@MSK | Save

[Fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) in subjects with HER2-positive metastatic breast cancer previously treated with T-DM1: A phase 2, multicenter, open-label study (DESTINY-Breast01)

Meeting Abstract

Krop, I. E.; Saura, C.; Yamashita, T.; Park, Y. H.; Kim, S. B.; Tamura, K.; André, F.; Iwata, H.; Ito, Y.; Tsurutani, J.; more...
Cancer Research (2020)

Fulltext@MSK | Save

T cell-based immunotherapy for a "public" neoantigen derived from a PIK3CA hotspot mutation

Meeting Abstract

Klebanoff, C.
Cancer Research (2020)

Fulltext@MSK | Save

A first-in-human phase Ia dose escalation study of GDC-0077, a p110a-selective and mutant-degrading PI3K inhibitor, in patients with PIK3CA-mutant solid tumors

Meeting Abstract

Juric, D.; Kalinsky, K.; Oliveira, M.; Cervantes, A.; Bedard, P.; Krop, I.; Hamilton, E.; Schmid, P.; Varga, A.; Turner, N.; more...
Cancer Research (2020)

Fulltext@MSK | Save

International, phase 3 trial: Balixafortide (a CXCR4 antagonist) + eribulin versus eribulin alone in patients with HER2 negative, locally recurrent or metastatic breast cancer (FORTRESS)

Meeting Abstract

Kaufmann, P.; Cortes, J.; Martin, M.; Mayer, I.; Vahdat, L.; Pernas, S.; Schmid, P.; McArthur, H.; Dent, R.; Rugo, H.; more...
Cancer Research (2020)

Fulltext@MSK | Save

Multiplatform analysis of matched primary and metastatic breast tumors from the AURORA US Network

Meeting Abstract

King, T. A.; Liu, M. C.; McClure, M. B.; Hinoue, T.; Kelly, B. J.; Creighton, C. J.; Bowen, J.; Leraas, K.; Burns, R. T.; Coppens, S.; more...
Cancer Research (2020)

Fulltext@MSK | Save

Randomized, doubleblind, phase 3 study of tucatinib or placebo in combination with T-DM1 for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer

Meeting Abstract

Hurvitz, S.; Vahdat, L.; Harbeck, N.; Wolff, A. C.; Tolaney, S. M.; Loi, S.; Masuda, N.; Dong, C.; Walker, L.; Rustia, E.; more...
Cancer Research (2020)

Fulltext@MSK | Save

Tumor ER protein modulation, molecular characterization and monitoring of cfDNA in phase 1 study of LSZ102 and LSZ102 + ribociclib in patients with ER+ MBC

Meeting Abstract

Jhaveri, K.; Juric, D.; Cresta, S.; Yap, Y. S.; Duhoux, F. P.; Terret, C.; Layman, R.; Balbin, A.; Sheng, Q.; Liao, S.; more...
Cancer Research (2020)

Fulltext@MSK | Save